News

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.
A new shot prevents HIV—and breathes new life into a stagnant biotech
Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...
Long-lasting HIV prevention shot headed toward approval
FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
Walmart's Flipkart has secured a lending licence from the Indian central bank and banking regulator, enabling it to offer ...
Long-lasting HIV prevention shot heads toward approval
A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.
Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"
NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However ...
Trump administration ending multiple HIV vaccine studies, scientists and officials say
The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...
Monitor on MSN8d
Gilead pushes on with HIV drug for poor nations despite funding crisis
Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...
Fierce Biotech15h
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification
Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...
Jefferies Maintains Buy Rating on Gilead Sciences (GILD), Cites Robust Pipeline
Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...
The Straits Times11d
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump ...